Lineage Cell Therapeutics Q2 EPS Reduced by HC Wainwright

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Research analysts at HC Wainwright lowered their Q2 2025 EPS estimates for Lineage Cell Therapeutics in a report released on Wednesday, May 14th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.02) for the quarter, down from their previous forecast of ($0.01). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q3 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.07) EPS.

A number of other brokerages have also recently weighed in on LCTX. B. Riley decreased their price target on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, March 14th. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $4.20.

Lineage Cell Therapeutics Trading Up 2.7%

Shares of NYSEAMERICAN:LCTX opened at $0.47 on Friday. The firm has a 50 day simple moving average of $0.46 and a 200-day simple moving average of $0.63. The company has a market capitalization of $103.71 million, a PE ratio of -3.92 and a beta of 1.21. Lineage Cell Therapeutics has a twelve month low of $0.37 and a twelve month high of $1.15.

Institutional Trading of Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC raised its stake in shares of Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after buying an additional 159,924 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Lineage Cell Therapeutics by 13.9% in the third quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company’s stock valued at $613,000 after purchasing an additional 82,864 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after acquiring an additional 18,053 shares during the last quarter. Defender Capital LLC. raised its stake in Lineage Cell Therapeutics by 19.2% in the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock valued at $2,997,000 after purchasing an additional 961,150 shares during the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new stake in Lineage Cell Therapeutics in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.